Biocon Limited today announced its financial performance for the three months ended June 30th, 2008.

PERFORMANCE HIGHLIGHTS

* Sales on a like for like basis (i.e. excluding enzymes) increased by 7%.
* Pre tax profits at a consolidated level were impacted by exchange losses across the group by Rs. 6 crores. A Mark to Market provision of Rs. 26 crores added to the impact.
* Absence of licensing income affected Q1 FY ‘09 profits. Licensing income is event driven and inherently variable across quarters. Licensing Income accounted for Rs. 17 crores in Q1 FY ’08.
* Biopharmaceutical business (excluding licensing income) showed 40% increase in PAT (from Rs. 28 crores in Q-1 FY ’08 to Rs. 39 crores in Q-1 FY’09) demonstrating strong profit growth in our core biopharmaceutical business.
* Branded formulations encompassing Cardio-Diabetes, Nephrology and Oncology delivered good growth.
* Syngene had a difficult quarter due to a number of factors. The impact of currency loss combined with operational delays resulted in a Rs. 6 crores decline in operating profit.
* Clinigene is now fully operational at its new facility and is on track to deliver 100% growth this fiscal.
* Biocon’s balance sheet remains strong. Net cash as on 30th June 2008 was Rs. 74 crores.
* Clinical development of the Company’s lead programs viz., IN105 (Oral Insulin) and T1h (Anti CD6 Monoclonal antibody) are progressing well.
* Biocon filed 23 new patents in Q1 FY ’09 bringing the total tally to 881 filed and 154 granted patents.
* Biocon has been ranked the 20th leading Biotechnology company in the world and No:1 in Asia by a reputed US trade journal.

Outlook:

Commenting on the results, Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited, said:

“Biocon’s Q1 FY ’09 performance has been unfortunately impacted by Rupee volatility which has seen us make a Mark to Market provision of Rs. 26 crores. We have consciously been conservative in making this provision. I believe that our business fundamentals are robust, which is well demonstrated by the strong profit growth in our core biopharmaceutical business. The absence of licensing income this quarter has had a disproportionate impact on profitability. However, we are confident that licensing income will be significant this fiscal. We are particularly encouraged by the good growth demonstrated by our branded formulations where several brands have attained high rankings in their product segments in India. INSUGEN® has now garnered an all India market share of ~15% in the vial segment.

Syngene has had a particularly difficult quarter. Management is confident of compensating for this in the quarters ahead especially with the BMS facility becoming fully operational in Q3 FY ’09.

Clinigene is now fully operational at its new facility and is on track to deliver good growth this fiscal.

We are making excellent progress on the research front with several programs approaching a licensing phase over the next 2 years, which is expected to provide attractive ROI.

We expect the quarters ahead to compensate for the exchange losses booked this quarter and end the year with improved profitability.”

CORPORATE DEVELOPMENTS:

Biocon to launch Abraxane on 18th July, 2008

Biocon Limited, India’s pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. ABRAXANE is now available in India as a single-use 100 mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). ABRAXANE is approved for marketing in 35 countries including USA and Europe.

Biocon to present IN105 data at EASD, 2008

Dr. Harish Iyer, Head of R&D will present the latest data on an ascending dose Phase IIa Clinical study on Type II Diabetic patients using IN 105 (Oral Insulin) at The European Association for the Study of Diabetes meeting to be held in Rome between September 8-11th 2008. This is the first time this data is being presented at a public forum. The data clearly establishes the linear dose related response of IN105 which paves the way forward for longer term clinical trials. Phase IIb/III clinical trials are being planned for later in the year.

Biocon is ranked 20th leading Biotechnology Company in the world by Med Ad News

Med Ad News, a leading US Trade publication, ranked Biocon at No. 20 in its 2007 list of Leading Global Biotechnology Companies, based on revenue and income . The report takes into consideration drug based firms, as these companies provide the best numbers to track the progress of the sector. Biocon Limited is the only Asian company to feature in the Top 25

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Biocon Group revenues Rs 1090cr, EBITDA Rs 335cr
• Gitanjali Gems revenues up 27% to Rs 1219.23 cr
• Kanoria Chemicals net profit at Rs 5.68cr
• Indo Asian Fusegear revenues increased by 24% to Rs 69.60cr
• R Systems reports revenues Rs 79.88cr